Quantcast
Last updated on April 23, 2014 at 17:28 EDT

Latest Lumiphore Inc. Stories

2014-04-17 16:26:59

Lumiphore Inc., a pharmaceutical leader in bifunctional chelator design, is developing in vivo radio-diagnostic imaging and site-directed radio-therapeutics, using its proprietary bifunctional radionuclide metal-chelation technology; it has received a National Science Foundation Small Business Innovation Research (SBIR) Phase II Grant entitled "Novel macrocyclic chelating groups for use in targeted radioisotope diagnostic and companion diagnostic/therapeutic applications." BERKELEY,...

2013-05-02 04:21:48

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4(®) bi-functional chelator technology and has extended the collaboration to include...

2010-10-21 07:00:00

RICHMOND, Calif., Oct. 21 /PRNewswire/ -- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a global agreement on incorporation of Lumiphore's Lumi4® complexes in Algeta's targeted radiotherapeutics and companion diagnostics. Under the agreement, Algeta has an option to...

2009-06-22 09:00:00

BERLIN, NIMES, France and RICHMOND, Calif., June 22 /PRNewswire/ -- BRAHMS Aktiengesellschaft, a global diagnostics company, Cezanne, and Lumiphore Inc., a biotechnology leader in new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that they have signed an agreement on incorporation of Lumiphore's Lumi4(R)-Tb complexes in BRAHMS diagnostic tests. Under the agreement, BRAHMS together with its subsidiary Cezanne, developer and manufacturer of...

2008-10-01 03:00:25

RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in the development of new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, California to apply Lumiphore products in diagnostic tests for drugs of abuse. Under the agreement, Biophor Diagnostics holds the exclusive worldwide rights to Lumi4(TM) technology in current and...